Until recently, there existed minimal guidance on the use of LC-MS for clinical diagnostics. The Clinical and Laboratory Standards Institute (CLSI) 2 has now presented a standardized approach for LC-MS assay development and verification in its new guidance document, CLSI C62-A. This document should aid in the harmonization of LC-MS methods and thus have significant ramifications for the evolution of this technology in the clinical laboratory. The ability to accurately identify and quantify a measurand with high sensitivity and specificity by use of selective reaction monitoring has been the driving force for the adoption of LC-MS in the clinical laboratory. LC-MS offers analytical specificity superior to that of widespread diagnostic methodologies such as immunoassays and enzymatic assays. Whereas immunoassays are commonplace in the clinical laboratory, they are not available for all analytes of interest, are plagued by specificity issues, and require the time-consuming production and evaluation of antibodies during development. Just as immunoassays have evolved since their development Ͼ50 years ago and have found their place as the leading automated technological approach to diagnostic testing, mass spectrometry (MS) will continue to progress and influence the clinical laboratory landscape. Therefore, standardization of the use of LC-MS is essential.
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Mass spectrometers were initially used in clinical laboratories only for specialized testing by highly trained and experienced operators. Today they are essential for the diagnosis of metabolic disorders, screening of diseases, quantification of hormone concentrations, monitoring of drug therapies, identification of microbial organisms, and recognition of drug toxicity and poisonings. Without the current clinical quantitative LC-MS methods, metabolic disorders would go undetected at birth, the accuracy of testosterone measurements for women and children would be equivalent to an educated guess, and monitoring of a variety of chemotherapeutics and immunosuppressants would be limited. Despite its widespread use, there is only 1 quantitative LC-MS assay approved by the US Food and Drug Administration (FDA); all other assays fall under the FDA classification of laboratory-developed test (LDT). An LDT is defined as an in vitro diagnostic test that is designed, manufactured, validated, and used within a single laboratory. Therefore, no 2 LC-MS methods for the same analyte are alike. The number of variables that could exist between any 2 LC-MS methods developed for the same purpose are too numerous to list, but include sample preparation method, instrumentation used, liquid chromatography stationary and mobile phases, MS source-and compound-dependent parameters, ion transitions monitored, and most importantly, calibrators used.
What Is the Current Status of Harmonization of Clinical LC-MS Methods?
Laboratory-to-laboratory variability for the same analyte, measured by LC-MS, has been observed as evidenced by results from external quality assessment programs and published reports. To date, few organized efforts have been made to harmonize LC-MS methods across different clinical laboratories. Unfortunately, there are very few higher-order reference measurement procedures and certified reference materials (CRMs) available for metrological traceability of analytes routinely monitored by clinical LC-MS methods. Only recently has there been an increase in the availability of accuracy-based proficiency testing for analytes commonly monitored by LC-MS; however, these surveys are still available only for vitamin D, estradiol, and testosterone.
A variety of CLSI guidance documents exist that aid clinical laboratories in the evaluation and routine use of clinical methods, but they are not specific to MS. CLSI C50 provides a general understanding of MS and the principles that dictate its application in the clinical laboratory but falls short of offering a systematic approach for method development and validation. Given the growing use of LC-MS in clinical laboratories and the wider range of people who use the technology, there is an increased need for robustness and harmonization of LC-MS methods. CLSI C62-A outlines the important elements for implementation of LC-MS in the clinical laboratory. It describes the common instrumentation used and important predevelopment considerations. Most importantly, it outlines best practices for assay development, preverification, verification, quality assessment, and postimplementation monitoring. Whereas many elements of CLSI C62-A can be found in various other published resources, such as a discussion of the instrumentation used, there are no other resources that comprehensively address specific clinical MS assay considerations. Table 1 provides a summary of the performance specifications and validation practices outlined in CLSI C62-A in comparison to those specified in the FDA's Guidance for Industry: Bioanalytical Method Validation (1 ) and the European Medicines Agency's Guideline on Bioanalytical Method Validation (2 ). It highlights the recommendations for accuracy, imprecision, sensitivity, matrix effects, specificity, carryover, analyte stability, dilutions, recovery, QC frequency, calibration standards, and linearity. Substantial similarity exists between the 3 documents; however, the new guideline provides a more comprehensive approach to the evaluation of trueness, interferences, carryover, and linearity. In the clinical setting, specific validation criteria may need to be developed for each analyte. The new CLSI document balances this need while providing a general approach to validation for all analytes.
What Are the Implications of CLSI C62-A for Clinical Laboratories?
Implementation of CLSI C62-A should result in the development of more robust clinical LC-MS assays and ultimately pave the way for improved harmonization. In theory, laboratories that are looking to implement LC-MS now have a comprehensive resource for development and validation of LC-MS assays. However, it is possible that the new guidelines could discourage some laboratories from incorporating MS due to the considerable challenges that it presents and large amount of work required for implementation, as highlighted in the guidance document. Laboratories that are already using LC-MS LDTs or are in the process of implementing a method may need to reevaluate their approach to ensure alignment with the new standards. Currently, validation of LDTs is evaluated by CLIA inspectors during biannual laboratory inspections. CLSI C62-A provides a framework for inspectors with which to ensure that all quantitative LC-MS LDTs are validated appropriately and meet standard acceptance criteria.
What Are the Implications of CLSI C62-A for Manufacturers?
Due to the increase in demand for LC-MS in the clinical laboratory, in recent years the major MS manufactures have obtained the appropriate International Organization for Standardization status for the design and manufacturing of medical devices. Today, there are a number of mass spectrometers listed as in vitro diagnostic medical devices; however, there is still only 1 quantitative LC-MS assay kit with FDA clearance. MS manufacturers legally cannot make claims about specific intended uses of their products and are therefore not immediately affected by the new guidelines. They are allowed to provide instruction on the appropriate use of their medical devices, and now they can point customers to CLSI C62-A for guidance. The new guidance document could have immediate ramifications for manufacturers of CRMs. CLSI C62-A recognizes that the first step toward harmonization is establishing metrological traceability to a stable reference. It specifies that CRMs should be used to validate calibrator value assignments for commercial calibrators or those prepared in-house, an essential step toward harmonization. Improper calibrator selection and value assignment is a major contributor to poor interlaboratory agreement. Ideally, the demand for CRMs will result in an increase in their production and availability from standard manufacturers.
The FDA is in the process of developing and eventually implementing a risk-based system for review of LDTs. With the FDA reasserting its right to regulate LDTs, the guidance provided by CLSI C62-A is very timely. The new FDA LDT proposed regulations could lead to an increase in the demand for FDA-approved MS methods. At the very least, the new guidance that CLSI C62-A provides and the increased scrutiny of LDTs by the FDA should propel MS manufacturers to provide more turnkey solutions for laboratories looking to harness the advantages LC-MS has to offer. Not addressed a CLSI C62-A specifies that "verification" is a 1-time process completed to determine or confirm test performance characteristics before the test system is used for patient testing. "Validation" (which is used to describe the FDA and EMA standards) is the action of proving that a procedure, process, system, equipment, or method works as expected and achieves the intended result. The components of validation, according to the CLSI document, are QC, proficiency testing, validation of employee competency, instrument calibration, and correlation with clinical findings. FDA and EMA use the term "validation" to describe what CLSI C62-A calls "verification." b RMP, reference measurement procedure; AMI, analytical measurement interval; LLOQ, lower limit of quantification; LLMI, lower limit of the measuring interval, formerly defined as the lower limit of quantification or LLOQ, as used in the FDA and EMA guidelines; ULMI, upper limit of the measuring interval, formerly defined as the upper limit of quantification or ULOQ, as used in the FDA and EMA guidelines; ULOQ, upper limit of quantification; S/N, signal to noise ratio; IS, internal standard.
What Will the Future Hold for Clinical MS Standardization?
CLSI C62-A highlights important considerations for method development, provides a framework for method validation, and defines acceptable performance for quantitative LC-MS methods; however, it does not cover all MS applications currently used in the clinical laboratory. Specific guidance for the validation of qualitative clinical MS methods still does not exist. Also, CLSI C62-A is specific to LC-MS methods that use selective reaction monitoring as their primary mode of mass selection.
Other methods operating in full-scan mode or centered on the collection of product ion spectra and library searching for compound or organism identification also have a substantial role in clinical diagnostics and are in need of standard guidance such as that provided by CLSI C62-A for quantitative methods. Other separation techniques, methods for MS sample introduction, and mass analyzers are gaining in popularity in specialized laboratories and could find their way to routine hospital laboratories in the future. As MS continues to gain in importance and influence in the clinical laboratory, the need for more guidance will continue. 
